The use of hyaluronic acid preparations in the treatment of osteoarthritis of the joints of the hands and knee joint


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Changes occurring in the synovial membrane and synovial fluid are the focus of specialists' attention. The article discusses the composition of synovial fluid, which functions as a medium through which nutrients and regulatory cytokines move. One of the components of synovial fluid is hyaluronic acid (HA) - a high-molecular substance from the group of glycosaminoglycans, which helps to retain moisture and preserve the elasticity of cartilage. Information about the structure, role, and interaction of HA with cytokines and other molecules is presented. A change in the structure and amount of HA in the synovial fluid is accompanied by a decrease in the protective function of the latter in relation to the joint tissues, which contributes to the progression of osteoarthritis. The article says that the concept of viscosuplementation (the introduction of exogenous HA) is considered justified, and the replacement of pathologically altered molecules allows to improve the rheological properties of synovial fluid, stimulate the synthesis of endogenous hyaluronic acid, preserve joint mobility, and reduce the intensity of pain. The results of clinical studies confirming this position are presented on the example of intra-articular administration of HA in the knee joints and hand joints. Particular attention is paid to the drug Fermatron, the evidence of the effectiveness of the safety of which is confirmed by international and Russian studies.

Full Text

Restricted Access

About the authors

Irina S. Dydykina

V.A. Nasonova Research Institute of Rheumatology

Email: dydykina_is@mail.ru
PhD, leading researcher of the Laboratory for the study of comorbid infections and monitoring the safety of antirheumatic drugs 115522, Moscow, 34A Kashirskoe Highway

Elizaveta V. Arutyunova

M.V. Lomonosov Moscow State University

Email: liza.arutyunova@mail.ru
student 119991, Moscow, 1 Leninskie gory Str

Polina S. Kovalenko

V.A. Nasonova Research Institute of Rheumatology

Email: polina_dydykinara@mail.ru
PhD, junior researcher of the Laboratory for monitoring the safety of antirheumatic drugs 115522, Moscow, 34A Kashirskoe Highway

Ekaterina V. Nikolaeva

V.A. Nasonova Research Institute of Rheumatology

Email: zoosad@inbox.ru
PhD, head of the Department of anesthesiology and resuscitation 115522, Moscow, 34A Kashirskoe Highway

References

  1. James S.L., Abate D., Abate K.H. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1789-858. doi: 10.1016/S0140-6736(18)32279-7.
  2. Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации в 201 5-2016 гг. Научно-практическая ревматология. 2018; 1: 15-21. doi: https://dx.doi.org/10.14412/1995-4484-2018-15-21.
  3. Балабанова Р.М., Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000-2010 гг. Научно-практическая ревматология. 2012; 3: 10-12. doi: https://dx.doi.org/10.14412/1995-4484-2012-702.
  4. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа. 2017; 464 с. ISBN 978-5-9704-4261-6.
  5. Айрапетов Г.А., Воротников А.А., Васюков В.А. Отек костного мозга в рамках суставной патологии. Инновационная медицина Кубани. 2020; 4: 58-64. doi: https://dx.doi.org/10.35401/2500-0268-2020-20-4-58-64.
  6. Standardization of osteoarthritis definitions, Osteoarthritis Research Society International. URL: https://www.oarsi.org/research/standardizationosteoarthritis-definitions. (date of access - 04.06.2017).
  7. Tamer T.M. Hyaluronan and synovial joint: function, distribution and healing. Interdisciplinary Toxicology. 2013; 6(3): 111-25. doi: 10.2478/intox-2013-0019.
  8. Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic acid in the Third Millennium. Polymers. 2018; 10(7): 701. doi: 10.3390/polym10070701.
  9. Necas J., Bartosikova L., Brauner P., Kolar J. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina. 2008; 53(8): 397-411. doi: 10.17221/1930-vetmed.
  10. Laurent T.C., Laurent U.B., Fraser J.R.E. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996; 74(2): A1-7. doi: 10.1038/icb.1996.32.
  11. Altman R., Manjoo A., Fierlinger A. et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015; 16: 321. doi: 10.1186/s12891-01 5-0775-z.
  12. Stern R., Jedrzejas M.J. Hyaluronidases: Their genomics, structures, and mechanisms of action. Chem Rev. 2006; 106(3): 818-39. doi: 10.1021/cr050247k.
  13. George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis. 1998; 57(11): 637-40. doi: 10.1136/ard.57.11.637.
  14. Sattar A., Kumar S., West D.C. Does hyaluronan have a role in endothelial cell proliferation of the synovium? Semin Arthritis Rheum. 1992; 22(1): 37-43. doi: 10.1016/0049-0172(92)90047-h.
  15. Edwards J. Second international meeting on synovium. Cell biology, physiology and pathology. 21-23 September, Canterbury, United Kingdom. Ann Rheum Dis. 1995; 54(5): 389-91. doi: 10.1136/ard.54.5.389.
  16. Cooper C., Rannou F., Richette P. et al. Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Arthritis Care Res (Hoboken). 2017; 69(9): 1287-96. doi: 10.1002/acr.23204.
  17. Bowman S., Awad M.E., Hamrick M.W. et al. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018; 7(1): 6. doi: 10.1186/s40169-017-0180-3.
  18. Balazs E.A., Denlinger J.L. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993; 39: 3-9.
  19. Bruyere O., Cooper C., Pelletier J. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum. 2014; 44(3): 253-63. doi: 10.1016/j.semarthrit.2014.05.014.
  20. Wobig M., Bach G., Beks P. et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999; 21(9): 1549-62. doi: 10.1016/s0149-2918(00)80010-7.
  21. Bongkotphet K., Tassanawipas W., Krittiyanunt S. et al. Comparative efficacy of low- and high- molecular weight intra-articular hyaluronic acids in patients with knee osteoarthritis. J Heal Res. 2009; 23: 87-92.
  22. Soltes L., Mendichi R. Molecular characterization of two host-guest associating hyaluronan derivatives. Biomed Chromatogr. 2003; 17(6): 376-84. doi: 10.1002/bmc.252.
  23. Lo G.H., LaValley M., McAlindon T., Felson D.T. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA. 2003; 290(23): 3115-21. doi: 10.1001/jama.290.23.3115.
  24. Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002; 32(1): 10-37. doi: 10.1053/sarh.2002.33720.
  25. Maneiro E., de Andres M.C., Fernandez-Sueiro J.L. et al. The biological action of hyaluronan on human osteoartritic articular chondrocytes: the importance of molecular weight. Clin Exp Rheumatol. 2004; 22(3): 307-12.
  26. Huang T.L., Hsu H.C., Yang K.C. et al. Effect of different molecular weight hyaluronans on osteoarthritis-related protein production in fibroblast-like synoviocytes from patients with tibia plateau fracture. J Trauma. 2010; 68(1): 146-52. doi: 10.1097/TA.0b013e3181a92cf8.
  27. Asari A., Miyauchi S., Matsuzaka S. et al. Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol. 1998; 61(2): 125-35. doi: 10.1679/aohc.61.125.
  28. Shewale A.R., Barnes C.L., Fischbach L.A. et al. Comparison of low-, moderate-, and high-molecular-weight hyaluronic acid injections in delaying time to knee surgery. J Arthroplasty. 2017; 32(10): 2952-57.e21. doi: 10.1016/j.arth.2017.04.041.
  29. Tikiz C., Unlu Z., Sener A. et al. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. 2005; 24(3): 244-50. doi: 10.1007/s10067-004-1013-5.
  30. Kotevoglu N., Iyibozkurt P.C., Hiz O. et al. A prospective randomised controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. 2006; 26(4): 325-30. doi: 10.1007/ s00296-005-0611-0.
  31. Zhao H., Liu H., Liang X. et al. Hylan G-F 20 versus low molecular weight hyaluronic acids for knee osteoarthritis: A meta-analysis. BioDrugs. 2016; 30(5): 387-96. doi: 10.1007/s40259-016-0186-1.
  32. Kusayama Y., Akamatsu Y., Kumagai K. et al. Changes in synovial fluid biomarkers and clinical efficacy of intra-articular injections of hyaluronic acid for patients with knee osteoarthritis. J Exp Orthop. 2014; 1(1): 16. doi: 10.1186/s40634-014-0016-7.
  33. Hermans J., Bierma-Zeinstra S.M.A., Bos P.K. et al. The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial. BMC Musculoskelet Disord. 2019; 20(1): 196. doi: 10.1186/s12891-019-2546-8.
  34. Михайлова А.С., Теплякова О.В., Соколова Л.А. Влияние локальной терапии гонартроза препаратами гиалуроновой кислоты различной молекулярной массы на динамику альгофункциональных индексов. Фарматека. 2011; 19: 74-78.
  35. Navarro-Sarabia F., Coronel P., Collantes E. et al. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011; 70(11): 1957-62. doi: 10.1136/ard.2011.152017.
  36. Fuchs S., Monikes R., Wohlmeiner A., Heyse T. Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis. Osteoarthritis Cartilage. 2006; 14(1): 82-88. doi: 10.1016/j.joca.2005.07.016.
  37. Monfort J., Rotes-Sala D., Segales N. et al. Comparative efficacy of intra-articular hyaluronic acid and corticoid injections in osteoarthritis of the first carpometacarpal joint: Results of a 6-month single-masked randomized study. Joint Bone Spine. 2015; 82(2): 116-21. doi: 10.1016/j.jbspin.2014.08.008.
  38. Orlandi D., Corazza A., Fabbro E. et al. Ultrasound-guided percutaneous injection to treat de Quervain's disease using three different techniques: a randomized controlled trial. Eur Radiol. 2014; 25(5): 1512-19. doi: 10.1007/s00330-014-3515-0.
  39. Altman R., Hackel J., Niazi F. et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Semin Arthritis Rheum. 2018; 48(2): 168-75. doi: 10.1016/j.semarthrit.2018.01.009.
  40. Елисеева Л.Н., Ждамарова О.И., Бледнова А.Ю. с соавт. Преимущества использования гиалуроната натрия при суставной патологии мелких суставов у полиморбидных пациентов. РМЖ. Медицинское обозрение. 2020; 2: 95-100. doi: https://dx.doi.org/10.32364/2587-6821-2020-4-2-95-100.
  41. Zhang B., Thayaparan A., Horner N. et al. Outcomes of hyaluronic acid injections for glenohumeral osteoarthritis: a systematic review and meta-analysis. J Shoulder Elbow Surg. 2019; 28(3): 596-606. doi: 10.1016/j.jse.2018.09.011.
  42. Maheu E., Bannuru R.R., Herrero-Beaumont G. et al. Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. Semin Arthritis Rheum. 2019; 48(4): 563-72. doi: 10.1016/j.semarthrit.2018.06.002.
  43. Kolasinski S.L., Neogi T., Hochberg M.C. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020; 72(2): 220-33. doi: 10.1002/art.41142.
  44. Kloppenburg M., Kroon F.P., Blanco F.J. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2018; 78(1): 16-24. doi: 10.1136/annrheumdis-2018-213826.
  45. Попов В.П., Корощенко С.А., Ларин М.А. Оптимальное использование препаратов гиалуроновой кислоты при суставной патологии. РМЖ. Медицинское обозрение. 2017; 1: 12-14.
  46. Bellamy N., Campbell J., Robinson V. et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005; 2: CD005321. doi: 10.1002/14651858.CD005321.
  47. Moghtaderi A., Sajadiyeh S., Khosrawi S. et al. Effect of subacromial sodium hyaluronate injection on rotator cuff disease: A doubleblind placebo-controlled clinical trial. Adv Biomed Res. 2013; 2: 89. doi: 10.4103/2277-9175.122517.
  48. Каплунов О.А., Каплунов К.О. Сравнительная эффективность курсовой инъекционной терапии Инъектраном или в комбинации с Ферматроном у пациентов с остеоартритом голеностопных суставов на фоне базового приема Генитрона. Эффективная фармакотерапия. 2019; 23: 18-24. doi: https://dx.doi.org/10.33978/2307-3586-2019-15-23-18-24.
  49. Привалов А.М. Тактика лечения тяжелой степени деформирующего артроза первого плюснефалангового сустава стопы. Поликлиника. 2019; 3: 60-62.
  50. Беляева Е.А., Авдеева О.С. Влияние вискосапплиментарной терапии с использованием гиалуроната натрия на потребность в эндопротезировании коленных суставов при остеоартрозе. РМЖ. 2017; 25: 1898-1904.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies